Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306409999> ?p ?o ?g. }
- W4306409999 abstract "Background Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation of arginase-1-specific T cells may convert the immunosuppressive tumor microenvironment and induce or strengthen local Th1 inflammation. In the current clinical study, we examined the safety and immunogenicity of arginase-1-based peptide vaccination. Methods In this clinical phase I trial, ten patients with treatment-refractory progressive solid tumors were treated. The patients received an arginase-1 peptide vaccine comprising three 20-mer peptides from the ARG1 immunological “hot spot” region in combination with the adjuvant Montanide ISA-51. The vaccines were administered subcutaneously every third week (maximum 16 vaccines). The primary endpoint was to evaluate safety assessed by Common Terminology Criteria for Adverse Events 4.0 and laboratory monitoring. Vaccine-specific immune responses were evaluated using enzyme-linked immune absorbent spot assays and intracellular cytokine staining on peripheral blood mononuclear cells. Clinical responses were evaluated using Response Evaluation Criteria in Solid Tumors 1.1. Results The vaccination was feasible, and no vaccine-related grade 3–4 adverse events were registered. Nine (90%) of ten patients exhibited peptide-specific immune responses in peripheral blood mononuclear cells. Six (86%) of the seven evaluable patients developed a reactive T cell response against at least one of the ARG1 peptides during treatment. A phenotypic classification revealed that arginase-1 vaccine-specific T cells were both CD4+ T cells and CD8+ T cells. Two (20%) of ten patients obtained stable disease for respectively four- and seven months on vaccination treatment. Conclusion The peptide vaccine against arginase-1 was safe. Nine (90%) of ten patients had measurable peptide-specific responses in the periphery blood, and two (20%) of ten patients attained stable disease on protocol treatment. Clinical trial registration https://clinicaltrials.gov/ct2/show/NCT03689192 , identifier NCT03689192." @default.
- W4306409999 created "2022-10-17" @default.
- W4306409999 creator A5013960209 @default.
- W4306409999 creator A5017721294 @default.
- W4306409999 creator A5019685539 @default.
- W4306409999 creator A5021651059 @default.
- W4306409999 creator A5047204650 @default.
- W4306409999 creator A5056529778 @default.
- W4306409999 creator A5073488854 @default.
- W4306409999 creator A5083898696 @default.
- W4306409999 creator A5089283847 @default.
- W4306409999 date "2022-10-17" @default.
- W4306409999 modified "2023-10-14" @default.
- W4306409999 title "Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial" @default.
- W4306409999 cites W1577847722 @default.
- W4306409999 cites W1921451985 @default.
- W4306409999 cites W192653885 @default.
- W4306409999 cites W1938515409 @default.
- W4306409999 cites W2000725338 @default.
- W4306409999 cites W2031352878 @default.
- W4306409999 cites W2054246680 @default.
- W4306409999 cites W2083970102 @default.
- W4306409999 cites W2120879968 @default.
- W4306409999 cites W2136502698 @default.
- W4306409999 cites W2138281334 @default.
- W4306409999 cites W2169083371 @default.
- W4306409999 cites W2297662468 @default.
- W4306409999 cites W2530067632 @default.
- W4306409999 cites W2768762480 @default.
- W4306409999 cites W2774484554 @default.
- W4306409999 cites W2785803176 @default.
- W4306409999 cites W2799710201 @default.
- W4306409999 cites W2809255841 @default.
- W4306409999 cites W2899369036 @default.
- W4306409999 cites W2944669048 @default.
- W4306409999 cites W2977846902 @default.
- W4306409999 cites W2987238277 @default.
- W4306409999 cites W3101247078 @default.
- W4306409999 cites W3134473205 @default.
- W4306409999 cites W3199710621 @default.
- W4306409999 cites W4200495164 @default.
- W4306409999 cites W4205492943 @default.
- W4306409999 cites W4206384730 @default.
- W4306409999 doi "https://doi.org/10.3389/fimmu.2022.1023023" @default.
- W4306409999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36330525" @default.
- W4306409999 hasPublicationYear "2022" @default.
- W4306409999 type Work @default.
- W4306409999 citedByCount "5" @default.
- W4306409999 countsByYear W43064099992023 @default.
- W4306409999 crossrefType "journal-article" @default.
- W4306409999 hasAuthorship W4306409999A5013960209 @default.
- W4306409999 hasAuthorship W4306409999A5017721294 @default.
- W4306409999 hasAuthorship W4306409999A5019685539 @default.
- W4306409999 hasAuthorship W4306409999A5021651059 @default.
- W4306409999 hasAuthorship W4306409999A5047204650 @default.
- W4306409999 hasAuthorship W4306409999A5056529778 @default.
- W4306409999 hasAuthorship W4306409999A5073488854 @default.
- W4306409999 hasAuthorship W4306409999A5083898696 @default.
- W4306409999 hasAuthorship W4306409999A5089283847 @default.
- W4306409999 hasBestOaLocation W43064099991 @default.
- W4306409999 hasConcept C137061746 @default.
- W4306409999 hasConcept C164007495 @default.
- W4306409999 hasConcept C202751555 @default.
- W4306409999 hasConcept C203014093 @default.
- W4306409999 hasConcept C22070199 @default.
- W4306409999 hasConcept C2776090121 @default.
- W4306409999 hasConcept C2777468819 @default.
- W4306409999 hasConcept C2777701055 @default.
- W4306409999 hasConcept C2777863537 @default.
- W4306409999 hasConcept C2780868878 @default.
- W4306409999 hasConcept C502942594 @default.
- W4306409999 hasConcept C515207424 @default.
- W4306409999 hasConcept C55493867 @default.
- W4306409999 hasConcept C71924100 @default.
- W4306409999 hasConcept C86803240 @default.
- W4306409999 hasConcept C8891405 @default.
- W4306409999 hasConceptScore W4306409999C137061746 @default.
- W4306409999 hasConceptScore W4306409999C164007495 @default.
- W4306409999 hasConceptScore W4306409999C202751555 @default.
- W4306409999 hasConceptScore W4306409999C203014093 @default.
- W4306409999 hasConceptScore W4306409999C22070199 @default.
- W4306409999 hasConceptScore W4306409999C2776090121 @default.
- W4306409999 hasConceptScore W4306409999C2777468819 @default.
- W4306409999 hasConceptScore W4306409999C2777701055 @default.
- W4306409999 hasConceptScore W4306409999C2777863537 @default.
- W4306409999 hasConceptScore W4306409999C2780868878 @default.
- W4306409999 hasConceptScore W4306409999C502942594 @default.
- W4306409999 hasConceptScore W4306409999C515207424 @default.
- W4306409999 hasConceptScore W4306409999C55493867 @default.
- W4306409999 hasConceptScore W4306409999C71924100 @default.
- W4306409999 hasConceptScore W4306409999C86803240 @default.
- W4306409999 hasConceptScore W4306409999C8891405 @default.
- W4306409999 hasLocation W43064099991 @default.
- W4306409999 hasLocation W43064099992 @default.
- W4306409999 hasLocation W43064099993 @default.
- W4306409999 hasOpenAccess W4306409999 @default.
- W4306409999 hasPrimaryLocation W43064099991 @default.
- W4306409999 hasRelatedWork W1992410431 @default.
- W4306409999 hasRelatedWork W1999684327 @default.
- W4306409999 hasRelatedWork W2018608294 @default.